This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Radius (RDUS) Announces Data on Breast Cancer Drug, Abalo-TDS
by Zacks Equity Research
Radius Health (RDUS) provides detailed results on breast cancer drug and from the phase III wearABLe study.
Radius (RDUS) Q3 Loss Wider Than Expected, Stock Declines
by Zacks Equity Research
Radius (RDUS) reports a year-over-year wider Q3 loss and misses on sales. The company also lowers guidance for lead drug Tymlos.
Radius Health (RDUS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Radius Health (RDUS) delivered earnings and revenue surprises of -74.07% and -7.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stocks' Q3 Earnings on Nov 8: VTRS, EDIT & More
by Kinjel Shah
Let us look at four drug/biotech companies, VTRS, RDUS, AXSM and EDIT, which are gearing up for their earnings release.
Earnings Preview: Radius Health (RDUS) Q3 Earnings Expected to Decline
by Zacks Equity Research
Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Radius (RDUS) Up On Positive Data From Breast Cancer Study
by Zacks Equity Research
Radius (RDUS) stock gains in response to positive results from a late-stage study evaluating breast cancer candidate, elacestrant.
Radius' (RDUS) Study on Tymlos for Osteoporosis in Men Meets Goal
by Zacks Equity Research
Radius (RDUS) reports positive top-line results from the ATOM study evaluating Tymlos (abaloparatide) subcutaneous injection for use in men with osteoporosis. The study met the primary endpoint.
Radius Health (RDUS) Stock Jumps 7.1%: Will It Continue to Soar?
by Zacks Equity Research
Radius Health (RDUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Radius (RDUS) Q2 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
Radius (RDUS) reports a narrower loss but misses on sales in the second quarter. The company also lowers guidance for lead drug Tymlos.
Radius Health (RDUS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Radius Health (RDUS) delivered earnings and revenue surprises of 10.26% and -12.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Radius Health (RDUS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Radius (RDUS) Q1 Loss Narrower than Expected, Revenues Lag
by Zacks Equity Research
Radius (RDUS) reports a narrower loss but misses on sales in the first quarter as lead drug sales decline.
Radius Health (RDUS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Radius Health (RDUS) delivered earnings and revenue surprises of 19.05% and -5.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Radius Health (RDUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Radius Health (RDUS) Up 14.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Radius Health (RDUS) Soars 14.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Radius Health (RDUS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
KemPharm (KMPH) Soars on FDA Nod for ADHD Treatment, Azstarys
by Zacks Equity Research
The FDA approves KemPharm's (KMPH) NDA for Azstarys for the treatment of attention deficit hyperactivity disorder in patients aged six years and older. Shares rise.
ChemoCentryx (CCXI) Q4 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the fourth quarter and misses on sales.
Radius' (RDUS) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Radius (RDUS) reports a wider loss but beats sales estimates in the fourth quarter.
Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
Pacira's (PCRX) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Exparel sales rise year over year.
Will Radius Health (RDUS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics
5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty
by Kinjel Shah
Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry in 2021. However, with demand trends expected to improve, USNA, RDUS, ONCT, ORGO and TPTX may prove to be good additions to one's portfolio.
What's in Store for Pacific Biosciences' (PACB) Q4 Earnings?
by Zacks Equity Research
Pacific Biosciences' (PACB) fourth-quarter results are likely to reflect strength in its Sequel system.
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.